What is Ketryx?
Ketryx operates at the intersection of artificial intelligence and medical device manufacturing, providing a sophisticated compliance platform that streamlines the product lifecycle. By integrating directly with existing engineering workflows, the company enables life science teams to automate complex documentation and traceability requirements. This approach significantly reduces the time-to-market for critical medical technologies while ensuring rigorous adherence to safety standards. Trusted by three of the world's top five medical device manufacturers, Ketryx has established itself as a vital infrastructure partner for organizations seeking to optimize their release cycles without compromising on quality or regulatory integrity.
How much funding has Ketryx raised?
Ketryx has raised a total of $89.1M across 3 funding rounds:
Series A
$14M
Series B
$39M
Private Equity
$36.1M
Series A (2023): $14M with participation from E14 Fund, Ubiquity Ventures, and Lightspeed Venture Partners
Series B (2025): $39M led by Lightspeed Venture Partners, MIT, Transformation Capital, and Ubiquity Ventures
Private Equity (2025): $36.1M, investors not publicly disclosed
Key Investors in Ketryx
Lightspeed Venture Partners
A global multistage venture capital firm that invests in early and growth-stage technology companies across sectors such as enterprise software, fintech, and infrastructure.
Transformation Capital
A growth equity fund headquartered in Boston that is fully focused on supporting innovative healthcare IT and services companies.
Ubiquity Ventures
A seed-stage institutional venture capital firm specializing in software beyond the screen, focusing on smart hardware and machine intelligence solutions.
What's next for Ketryx?
With this major enterprise-level funding, Ketryx is poised to deepen its market penetration and expand its suite of automated compliance tools. The strategic focus will likely center on scaling its AI-driven engine to handle increasingly complex regulatory environments, thereby maintaining its competitive edge in the life sciences software market. By leveraging the expertise of its diverse investor base, the company is expected to enhance its operational efficiency and continue its trajectory as a leader in digital health transformation. Future initiatives will likely prioritize the integration of advanced machine learning models to further reduce manual overhead for its enterprise clients, ensuring that Ketryx remains the standard for high-velocity, compliant product development.
See full Ketryx company page
